Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles BMC Cancer Year : 2011

Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer.

Isabelle Treilleux
  • Function : Author
  • PersonId : 905073
Isabelle Ray-Coquard
  • Function : Author
  • PersonId : 905074
Olivier Trédan
  • Function : Author
  • PersonId : 905077
Sophie Goddard-Léon
  • Function : Author
  • PersonId : 905078
Jean-Jacques Pin
  • Function : Author
  • PersonId : 905079
Hervé Mignotte
  • Function : Author
  • PersonId : 905080
Clarisse Bathélémy-Dubois
  • Function : Author
  • PersonId : 905081
Christophe Caux
  • Function : Author
  • PersonId : 905082
Serge Lebecque
  • Function : Author
  • PersonId : 905083

Abstract

ABSTRACT: BACKGROUND: Chemokines and chemokine receptors are major actors of leukocytes trafficking and some have been shown to play an important role in cancer metastasis. Chemokines CCL19, CCL20 and CCL21 and their receptors CCR6 and CCR7, were assessed as potential biomarkers of metastatic dissemination in primary breast cancer. Methods: Biomarker expression levels were evaluated using immunohistochemistry on paraffin-embedded tissue sections of breast cancer (n=207). Results: CCR6 was expressed by tumor cells in 35% of cases. CCR7 was expressed by spindle shaped stromal cells in 43% of cases but not by tumor cells in this series. CCL19 was the only chemokine found expressed in a significant number of breast cancers and was expressed by both tumor cells and dendritic cells (DC). CCR6, CCL19 and CCR7 expression correlated with histologic features of aggressive disease. CCR6 expression was associated with shorter relapse-free survival (RFS) in univariate and but not in multivariate analysis (p = 0.0316 and 0.055 respectively), and was not associated with shorter overall survival (OS). Expression of CCR7 was not significantly associated with shorter RFS or OS. The presence of CCL19-expressing DC was associated with shorter RFS in univariate and multivariate analysis (p = 0.042 and 0.020 respectively) but not with shorter OS. Conclusion: These results suggest a contribution of CCR6 expression on tumor cells and CCL19-expressing DC in breast cancer dissemination. In our series, unlike what was previously published, CCR7 was exclusively expressed on stromal cells and was not associated with survival.

Domains

Cancer
Fichier principal
Vignette du fichier
1471-2407-11-213.pdf (654.97 Ko) Télécharger le fichier
1471-2407-11-213-S1.PPT (351.5 Ko) Télécharger le fichier
1471-2407-11-213-S2.PPT (3.4 Mo) Télécharger le fichier
1471-2407-11-213.xml (91.73 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Format : Other
Format : Other
Format : Other
Loading...

Dates and versions

inserm-00606545 , version 1 (06-07-2011)

Identifiers

Cite

Philippe Cassier, Isabelle Treilleux, Thomas Bachelot, Isabelle Ray-Coquard, Nathalie Bendriss-Vermare, et al.. Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer.. BMC Cancer, 2011, 11 (1), pp.213. ⟨10.1186/1471-2407-11-213⟩. ⟨inserm-00606545⟩
149 View
299 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More